C3435T Mutation in Exon 26 of the Human MDR1 Gene and Cyclosporine Pharmacokinetics in Healthy Subjects
- 1 June 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 24 (3) , 400-404
- https://doi.org/10.1097/00007691-200206000-00012
Abstract
To determine the relationship between C3435T mutation in exon 26 of the human multidrug resistant 1 (MDR1) gene and cyclosporine pharmacokinetic parameters among healthy volunteers, the oral cyclosporine pharmacokinetic study was performed for 14 healthy subjects. Blood cyclosporine concentrations were measured by HPLC. Concentration–time data were analyzed by a noncompartmental method using WinNonLin, and the blood samples were genotyped for the C3435T polymorphism of MDR1 gene using the PCR and a restriction digest. Each cyclosporine pharmacokinetic parameter was compared using the Mann-Whitney U test according to his or her P-gp genotype. There were seven (7) homozygous C/C, six (6) C/T, and one (1) homozygous T/T genotypes in these 14 healthy volunteers. According to their genotypes, mean tmax 1.6 ± 0.3 hours, mean Cmax 1337 ± 329 ng/mL, mean Cl/F 66.5 ± 18.3 L/h, and mean AUC 5642 ± 1577 ng·h/mL in C/C group and mean tmax 2.0 ± 0.6 hours, mean Cmax 1540 ± 721 ng/mL, mean Cl/F 55.2 ± 18.9 L/h, and mean AUC 6902 ± 1405 ng·h/mL in C/T+T/T group. Although Cmax and AUC in C/T and T/T group were 15% and 22% larger than those in C/C group, none of these parameter comparisons was statistically significant. There were no statistical differences in cyclosporine pharmacokinetics among different MDR1 genotypes in these 14 healthy subjects.Keywords
This publication has 18 references indexed in Scilit:
- CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphismClinical Pharmacology & Therapeutics, 2000
- Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipientClinical Pharmacology & Therapeutics, 2000
- Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProceedings of the National Academy of Sciences, 2000
- P‐glycoprotein and Drug Therapy in Organ TransplantationThe Journal of Clinical Pharmacology, 1999
- Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-GlycoproteinPharmaceutical Research, 1999
- Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*Clinical Pharmacology & Therapeutics, 1997
- P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.Proceedings of the National Academy of Sciences, 1996
- Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapyMolecular Carcinogenesis, 1995
- Enzymatic Oxidation of Xenobiotic ChemicalCritical Reviews in Biochemistry and Molecular Biology, 1990
- Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugsClinical Pharmacology & Therapeutics, 1988